OS Therapies Inc (OSTX)
OS Therapies Incorporated, a clinical stage biopharmaceutical company, focuses on the identification, development, and commercialization of treatments for osteosarcoma and other solid tumors in the United States. Its pipeline includes OST-HER2, an off-the-shelf immunotherapy for osteosarcoma patients; and OST-tunable drug conjugate (OST-tADC), an antibody-drug conjugate (ADC) silicone dioxide linker technology, with a plug-and-play platform that features tunable pH sensitive silicone linkers. OS Therapies Incorporated was incorporated in 2018 and is based in Grasonville, Maryland.
Sector: Pharmaceutical Preparations
Industry: Biotechnology
OS Therapies Incorporated
NYSE:OSTXHealthcare · Biotechnology
PrePre-market+0.00%$1.21
Close$1.21-3.20%
AH Close$1.22+0.83%vs close
Close$1.21-3.20%AH Close$1.22+0.83%vs close
Mkt Cap-
Float43.5M
O/S-
Inst Own6.2%
Dilution
Delisting Issues Timeline
Financials Summary
Revenue$0
Net Income-$28.75M
Total Assets$6.84M
Free Cash Flow-$14.24B
Debt & Equity
Total Debt$0
Total Equity-$6.1M
Shares Outstanding
Short Interest
Split History
No splits on record
Nothing in OSTX's public trading history: no forward or reverse split has affected the share count.
Balance Sheet Details
Assets$6.84M
Liabilities$12.94M
Accounts Receivable$0
Accounts Payable$9.94M
Inventory$0
PP&E (Net)$2K
Goodwill$0
Intangible Assets$6.5M
Income Statement
| Period | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
|---|---|---|---|---|---|---|
| Currency | USD | USD | USD | USD | USD | USD |
| Period Ending | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 | 2020-12-31 |
| Revenue | $0 | $0 | $0 | $0 | $0 | $0 |
| YoY Growth | - | - | - | - | - | - |
| Cost of Revenue | $363K | $3K | $4K | $805 | $1.16M | $4K |
| Gross Profit | -$363K | -$3K | -$4K | -$805 | -$1.16M | -$4K |
| Gross Margin | - | - | - | - | - | - |
| Research and Development | $16.36B | $2.84M | $3.22M | $3.29M | $2.17M | $602 |
| Selling, General, and Administrative | $12.34B | $3.97M | $1.12M | $1.15M | $1.5M | $795 |
| Other | -$28.68B | $0 | $5K | $1K | -$0 | $0 |
| Total Operating Expenses | $28.34M | $6.81M | $4.34M | $4.45M | $3.68M | $1K |
| Operating Income (EBIT) | -$28.71M | -$6.81M | -$4.34M | -$4.45M | -$4.84M | -$6K |
| Operating Margin | - | - | - | - | - | - |
| Interest Expense | $0 | $2.05M | $3.45M | $1.81M | $2.58M | $461.79M |
| Interest Income | $249 | $0 | $0 | $0 | $0 | $81.28M |
| Other Income (Expense) | -$48K | -$2.07M | -$3.45M | -$1.81M | -$2.58M | -$381 |
| Income Before Tax (EBT) | -$28.75M | -$8.88M | -$7.79M | -$6.25M | -$7.42M | -$6K |
| Income Tax Expense | $0 | $0 | $0 | $0 | $0 | $0 |
| Net Income | -$28.75M | -$8.88M | -$7.79M | -$6.25M | -$7.42M | -$6K |
| Net Income Margin | - | - | - | - | - | - |
| Supplementary Data | ||||||
| EPS | -0.98 | -0.52 | -0.39 | -0.28 | -0.33 | -0.00 |
| Diluted EPS | -0.98 | -0.52 | -0.39 | -0.28 | -0.33 | -0.00 |
| Weighted Average OS | 29.25M | 20.87M | 20.05M | 23.10M | 23.10M | 8.42M |
| EBITDA | -$28.39M | -$6.83M | -$4.34M | -$4.45M | -$4.84M | $61K |
| EBITDA Margin | - | - | - | - | - | - |
Balance Sheet
| Period | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
|---|---|---|---|---|---|---|
| Currency | USD | USD | USD | USD | USD | USD |
| Period Ending | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 | 2020-12-31 |
| Assets | ||||||
| Current Assets | ||||||
| Cash and Cash Equivalents | $270K | $5.53M | $39K | $171K | $81K | $1.23B |
| Short-Term Investments | $0 | $0 | $0 | $0 | $0 | $0 |
| Cash and Short-Term Investments | $270K | $5.53M | $39K | $171K | $81K | $1.23B |
| Accounts Receivable | $0 | $0 | $0 | $1K | $231K | $430.49M |
| Inventory | $0 | $0 | $0 | $0 | $0 | $0 |
| Other Current Assets | $0 | $0 | $751K | $324K | $0 | $12.8M |
| Total Current Assets | $333K | $5.53M | $790K | $497K | $313K | $1.68B |
| Long-Term Assets | ||||||
| Property, Plant & Equipment Net | $2K | $5K | $8K | $12K | $13K | $1.95M |
| Goodwill | $0 | $0 | $0 | $0 | $0 | $0 |
| Intangible Assets | $6.5M | $0 | $0 | $0 | $0 | $0 |
| Long-Term Investments | $0 | $0 | $0 | $0 | $0 | $0 |
| Deferred Tax Assets | $0 | $0 | $0 | $0 | $0 | $0 |
| Other Long-Term Assets | $0 | $0 | $0 | $0 | $0 | $0 |
| Total Long-Term Assets | $6.51M | $5K | $8K | $12K | $13K | $1.95M |
| Other Assets | $0 | $0 | $0 | $0 | $0 | $0 |
| Total Assets | $6.84M | $5.54M | $798K | $509K | $326K | $1.68B |
| Liabilities | ||||||
| Current Liabilities | ||||||
| Accounts Payable | $9.94M | $1.66M | $2.72M | $1.23M | $857K | $40K |
| Short-Term Debt | $0 | $0 | $14.61M | $0 | $0 | $871.25M |
| Current Income Tax Payable | $0 | $0 | $0 | $426K | $367K | $0 |
| Current Unearned Revenue | $0 | $0 | $0 | $0 | $0 | $0 |
| Other Current Liabilities | $0 | $2.35M | $4.71M | $3.04M | $1.61M | $809.03M |
| Total Current Liabilities | $11.76M | $4.63M | $24.71M | $6.15M | $3.5M | $2.1B |
| Long-Term Liabilities | ||||||
| Long-Term Debt | $0 | $0 | $0 | $10.35M | $7.07M | $5.9B |
| Long-Term Unearned Revenue | $100K | $0 | $100K | $100K | $100K | $0 |
| Long-Term Deferred Tax Liabilities | $0 | $0 | $0 | $0 | $0 | $0 |
| Other Long-Term Liabilities | $1.07M | $100K | $0 | $1.47M | $1.11M | $0 |
| Total Long-Term Liabilities | $1.17M | $100K | $100K | $11.92M | $8.28M | $5.9B |
| Other Liabilities | $0 | $0 | $0 | $0 | $0 | $0 |
| Total Liabilities | $12.94M | $4.73M | $24.81M | $18.07M | $11.78M | $8B |
| Stockholders' Equity | ||||||
| Preferred Stock | $0 | $6.05M | $1K | $1K | $1K | $0 |
| Common Stock | $37K | $21K | $5K | $5K | $10K | $8.84M |
| Retained Earnings | -$67.19M | -$40.4M | -$29.52M | -$21.6M | -$15.22M | -$6.34B |
| Comprehensive Income & Other | $0 | $0 | $0 | $0 | $0 | $0 |
| Other Stockholders' Equity | $61.05M | $41.19M | $5.5M | $4.04M | $3.76M | $0 |
| Total Equity | -$6.1M | $811K | -$24.02M | -$17.56M | -$11.45M | -$6.33B |
| Minority Interest | $0 | $0 | $0 | $0 | $0 | $0 |
| Total Liabilities and Equity | $6.84M | $5.54M | $798K | $509K | $326K | $1.68B |
| Supplementary Data | ||||||
| Total Debt | $0 | $0 | $14.61M | $10.35M | $7.07M | $6.77B |
| Net Debt | -$270K | -$5.53M | $14.57M | $10.18M | $6.99M | $5.54B |
Cash Flow Statement
| Period | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
|---|---|---|---|---|---|---|
| Currency | USD | USD | USD | USD | USD | USD |
| Period Ending | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 | 2020-12-31 |
| Operating Activities | ||||||
| Net Income | -$28.75B | -$8.88M | -$7.79M | -$6.25M | -$7.42M | -$6.03B |
| Depreciation & Amortization | $363K | $3K | $4K | $805 | $805 | $67K |
| Deferred Income Tax | $0 | $0 | $0 | $0 | $0 | $0 |
| Stock-Based Compensation | $4.27B | $268K | $0 | $0 | $0 | $0 |
| Changes in Working Capital: | ||||||
| Accounts Receivable | $0 | $0 | $0 | $0 | $0 | $0 |
| Inventory | $0 | $0 | $0 | $0 | $0 | $0 |
| Accounts Payable | $8.27M | -$1.05M | $1.35M | $216K | $856K | $9K |
| Other Working Capital | $835K | $924K | $670K | $731K | -$282K | $964.38M |
| Total Working Capital Change | $9.11M | -$130K | $2.02M | $947K | $575K | $964.39M |
| Other Non-Cash Items | $10.24B | $1.46M | $2.76M | $1.51M | $2.44M | $2.65B |
| Net Cash from Operating | -$14.24B | -$7.28M | -$3.01M | -$3.79M | -$4.4M | -$2.41B |
| Investing Activities | ||||||
| Capital Expenditures | -$466K | $0 | $0 | $0 | -$12K | -$2.01M |
| Acquisitions | $0 | $0 | $0 | $0 | $0 | $0 |
| Purchases of Investments | $0 | $0 | $0 | $0 | $0 | $0 |
| Sales of Investments | $0 | $0 | $0 | $0 | $0 | $0 |
| Other Investing Activities | -$465.96M | $0 | $1K | $231K | $212K | $160.3M |
| Net Cash from Investing | -$466.42M | $0 | $1K | $231K | $200K | $158.29M |
| Financing Activities | ||||||
| Debt Repaid | - | -$1.5M | -$3.16M | -$3.82M | -$2.95M | -$3.48B |
| Common Stock Issuance | $8.39M | $5.23M | $0 | $0 | $0 | $2.1M |
| Common Stock Repurchases | $0 | $0 | $0 | $0 | $0 | $0 |
| Dividends Paid | $0 | -$31.25M | $0 | $0 | $0 | $0 |
| Other Financing Activities | $9.43B | $31.25M | -$284K | -$172K | $100K | $0 |
| Net Cash from Financing | $9.44B | $12.78M | $2.87M | $3.65M | $3.05M | $3.48B |
| Forex Effect | $0 | $0 | $0 | $0 | $0 | $9.94M |
| Net Change in Cash | -$5.26B | $5.49M | -$132K | $91K | -$1.15M | $1.23B |
| Supplementary Data | ||||||
| Operating Cash Flow | -$14.24B | -$7.28M | -$3.01M | -$3.79M | -$4.4M | -$2.41B |
| Capital Expenditure | -$466K | $0 | $0 | $0 | -$12K | -$2.01M |
| Free Cash Flow | -$14.24B | -$7.28M | -$3.01M | -$3.79M | -$4.41M | -$2.42B |
| Cash at Beginning | $5.53B | $39K | $171K | $81K | $1.23M | $0 |
| Cash at End | $269.83M | $5.53M | $39K | $171K | $81K | $1.23B |